Gh Research Plc Stock Price, News & Analysis
Company Description
GH Research PLC (NASDAQ: GHRS) is a clinical-stage biopharmaceutical company focused on developing novel mebufotenin-based therapies for depression and other psychiatric disorders. The company describes itself as dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, with an initial focus on treatment-resistant depression (TRD).
According to company disclosures, GH Research PLC operates with a single reportable segment dedicated to research and development. Its development portfolio centers on mebufotenin product candidates designed for different routes of administration and clinical settings. The lead candidate, GH001, is a proprietary inhalable mebufotenin product candidate, while GH002 is a proprietary intravenous mebufotenin product candidate. Both are being investigated for their potential to provide rapid and durable antidepressant effects.
Core product candidates and clinical focus
The company reports that GH001 is formulated for mebufotenin administration via a proprietary inhalation approach. GH001 has been evaluated in a multi-center, randomized, double-blind, placebo-controlled Phase 2b clinical trial in patients with treatment-resistant depression (GH001-TRD-201). GH Research states that this trial met its primary endpoint, with a placebo-adjusted reduction from baseline of 15.5 points in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score on Day 8, and that all secondary endpoints were also met with clinically and statistically significant improvements on Day 8 compared with placebo.
The company further reports that an open-label extension (OLE) of this Phase 2b trial showed a 73% remission rate at six months among participants, with infrequent treatment visits and no mandated psychotherapeutic intervention. GH Research highlights that in the double-blind and OLE phases, there were no treatment-related serious adverse events and no treatment-emergent events of suicidal intent or suicidal behavior during the six-month duration of the trial. The psychoactive experience associated with GH001 in this trial had a median duration of approximately 11 minutes, and the company notes that 99% of patients were considered discharge-ready within one hour of dosing across treatment visits.
Beyond TRD, GH Research has conducted Phase 2a proof-of-concept trials with GH001 in postpartum depression (PPD) and in bipolar II disorder with a current major depressive episode (BDII). The company reports that both trials met their primary endpoints, with substantial reductions in MADRS scores by Day 8 and favorable tolerability profiles, including no treatment-related serious adverse events and no reported treatment-emergent hypomania or mania in the BDII trial.
GH002, the company’s intravenous mebufotenin product candidate, has completed a Phase 1, dose-ranging clinical pharmacology trial in healthy volunteers. GH Research states that GH002 was well tolerated, with no severe or serious adverse events, and produced ultra-rapid psychoactive effects. The pharmacokinetic profile of GH002 is described as equivalent to that of GH001.
Regulatory interactions and development pathway
GH Research has disclosed extensive regulatory engagement around GH001. Its Investigational New Drug Application (IND) for GH001 administered using a proprietary aerosol delivery device was previously placed on clinical hold by the U.S. Food and Drug Administration (FDA). The company reports that the FDA requested additional inhalation toxicology studies in rats and a non-rodent species, device design verification information, and updates to the investigator brochure. GH Research has stated that these studies were completed, that the non-rodent study showed no respiratory tract histology findings in dogs at any dose level evaluated, and that rat findings were consistent with prior studies, supporting the company’s view that they are rat-specific.
In June 2025, GH Research announced that it had submitted a complete response to the FDA’s clinical hold. Subsequent disclosures indicate that the FDA’s feedback left one hold topic remaining, related to respiratory tract histology findings in rats, and that engagement with the agency continued. In January 2026, the company announced that the FDA had lifted the clinical hold on GH001’s IND, clearing GH001 for U.S. clinical investigation and enabling U.S. subject enrollment. GH Research has indicated that it plans to seek FDA alignment on a global Phase 3 program for GH001 in TRD, aiming to replicate the Phase 2b design in a pivotal setting.
To support its global program, GH Research is also conducting a Phase 1 clinical pharmacology trial (GH001-HV-106) to evaluate its proprietary aerosol delivery device for GH001 administration in healthy volunteers in the United Kingdom. This trial is described as a bridge to clinical data generated with a commercially available device used in earlier trials.
Scientific and clinical community engagement
GH Research regularly presents its clinical data at major psychiatric and neuropsychopharmacology conferences. The company has announced presentations and posters at events such as the European College of Neuropsychopharmacology (ECNP) Congress, the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, the International Society for Bipolar Disorders (ISBD) Annual Meeting, and the American College of Neuropsychopharmacology (ACNP) annual meeting. These presentations have covered topics including long-term safety and efficacy data from the GH001-TRD-201 OLE, psychoactive effects of GH001 in TRD, safety and tolerability results from the Phase 2b trial, and proof-of-concept data in postpartum depression and bipolar II disorder.
According to abstracts and commentary cited by GH Research, external academic investigators have emphasized the rapid antidepressant effects, favorable tolerability, and potential for GH001 to function as a rapid-acting treatment option in TRD and related conditions. The company also notes that it has organized an industry satellite symposium to discuss rapid-acting antidepressants in TRD.
Financial profile and capital resources
GH Research reports that it is a clinical-stage company without approved products and that its activities are concentrated in research and development. The company’s financial statements show operating expenses primarily in research and development and general and administrative categories, with recurring net losses consistent with an R&D-focused biopharmaceutical enterprise.
The company has disclosed significant cash, cash equivalents, other financial assets, and marketable securities on its balance sheet, and has reported proceeds from a public offering. These resources are described as supporting ongoing clinical development, regulatory interactions, and corporate operations. GH Research files its financial statements under International Financial Reporting Standards (IFRS) and furnishes them to the U.S. Securities and Exchange Commission (SEC) on Form 6-K.
Business model and strategic focus
GH Research’s business model, as described in its public communications, centers on discovering, developing, and clinically validating mebufotenin-based therapies for psychiatric and neurological disorders, with a primary focus on treatment-resistant depression. The company’s strategy emphasizes:
- Advancing GH001 through late-stage clinical development in TRD, including a planned global pivotal program.
- Expanding the clinical evidence base for GH001 in additional depressive conditions such as postpartum depression and bipolar II disorder.
- Developing GH002 as an intravenous mebufotenin candidate with a pharmacokinetic profile equivalent to GH001.
- Collaborating with academic investigators and presenting data at scientific congresses to build clinical and scientific support for its programs.
According to its disclosures, GH Research believes that the clinical activity observed in its Phase 2b TRD trial and Phase 2a proof-of-concept studies supports the potential of its mebufotenin product candidates to change how TRD is treated.
Exchange listing and jurisdiction
GH Research PLC’s ordinary shares trade on the Nasdaq stock market under the ticker symbol GHRS. The company is organized as a foreign private issuer and files reports with the SEC, including Form 20-F and periodic Form 6-K current reports. Its principal executive office is located in Dublin, Ireland, as indicated in its SEC filings.
FAQs about GH Research PLC (GHRS)
- What does GH Research PLC do?
GH Research PLC is a clinical-stage biopharmaceutical company focused on developing novel and proprietary mebufotenin therapies, with an initial emphasis on treatment-resistant depression. Its activities are concentrated in research and development of product candidates such as GH001 and GH002.
- What is GH001?
GH001 is GH Research’s lead product candidate, formulated for mebufotenin administration via a proprietary inhalation approach. It has been studied in a Phase 2b randomized, double-blind, placebo-controlled trial in treatment-resistant depression (GH001-TRD-201), where the company reports that the primary endpoint was met with a significant placebo-adjusted MADRS reduction on Day 8.
- What is GH002?
GH002 is a proprietary intravenous mebufotenin product candidate developed by GH Research. The company has completed a Phase 1, dose-ranging clinical pharmacology trial of GH002 in healthy volunteers and reports that GH002 was well tolerated, produced ultra-rapid psychoactive effects, and had a pharmacokinetic profile equivalent to GH001.
- Which conditions is GH Research targeting?
GH Research’s initial focus is on treatment-resistant depression. The company has also conducted Phase 2a proof-of-concept trials of GH001 in postpartum depression and in bipolar II disorder with a current major depressive episode, and it describes itself as dedicated to transforming the treatment of psychiatric and neurological disorders.
- What were the key findings from the GH001 Phase 2b TRD trial?
In the GH001-TRD-201 Phase 2b trial in treatment-resistant depression, GH Research reports that the primary endpoint was met with a placebo-adjusted MADRS reduction from baseline of 15.5 points on Day 8 (p<0.0001). The company also notes high remission rates at Day 8 and at six months in the open-label extension, infrequent treatment visits, and no treatment-related serious adverse events or treatment-emergent suicidal intent or behavior over six months.
- Has the FDA lifted the clinical hold on GH001?
Yes. GH Research announced that the U.S. Food and Drug Administration has lifted the clinical hold on its Investigational New Drug Application for GH001, clearing GH001 for clinical investigation in the United States and enabling enrollment of U.S. subjects.
- What is GH Research’s stock symbol and where is it listed?
GH Research PLC’s ordinary shares trade on the Nasdaq stock market under the ticker symbol GHRS. The company is a foreign private issuer and submits reports to the U.S. Securities and Exchange Commission.
- How does GH Research describe its business segment?
The company states that it has a single segment focused on research and development. Its financial reports present operating expenses primarily in research and development and general and administrative categories.
- Where is GH Research based?
SEC filings list GH Research PLC’s principal executive office in Dublin, Ireland. The company also conducts clinical and scientific activities in multiple countries through its trials and conference participation.
- What types of clinical data does GH Research present at conferences?
GH Research has presented data on GH001’s long-term safety and efficacy in treatment-resistant depression, psychoactive effects in TRD, safety and tolerability in Phase 2b and open-label extension settings, and proof-of-concept results in postpartum depression and bipolar II disorder, as well as broader discussions on rapid-acting antidepressants.